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Background: The role of prophylactic cranial irradiation (PCI) on small cell lung cancer (SCLC) has been established
based on the two-stage system of limited versus extensive disease and the treatment modality of chemoradiotherapy.
However, the use of PCI after combined-modality treatment with surgery for resectable limited-stage SCLC has not
been investigated sufficiently. We conducted a retrospective study to evaluate risk factors for brain metastasis (BM) in
patients with surgically resected SCLC to identify those most likely to benefit from PCI.
Patients and methods: The records of 126 patients with completely resected SCLC and definitive TNM stage based
on histological examination between 2003 and 2009 were reviewed. The cumulative incidence of BM was estimated
using the Kaplan–Meier method and differences between the groups were analyzed using the log-rank test.
Multivariate Cox regression analysis was applied to assess the risk factors of BM.
Results: Twenty-eight patients (22.2%) developed BM at some point during their clinical course. The actuarial
risk of developing BM at 3 years was 9.7% in patients with p-stage I disease, 18.5% in patients with p-stage II
disease, and 35.4% in patients with p-stage III disease (p = 0.013). The actuarial risk of developing BM at 3 years
in patients with LVI was 39.9% compared to 17.5% in patients without LVI (p = 0.003). Multivariate analysis
identified pathologic stage (hazard ratio [HR] = 2.013, p = 0.017) and LVI (HR = 1.924, p = 0.039) as independent
factors related to increased risk of developing BM.
Conclusion: Patients with completely resected p-stage II-III SCLC and LVI are at the highest risk for BM.
Keywords: Small cell lung cancer, Brain metastases, Prophylactic cranial irradiation, Risk factors,
Lymphovascular invasion, Pathologic stageBackground
Small cell lung cancer (SCLC) accounts for approximately
15%–20% of all lung cancers [1]. It is characterized by a
high incidence of metastatic disease at presentation, rapid
doubling time, and a high response rate to treatment [2].
Despite a high response to chemotherapy (ChT) and radi-
ation therapy, most patients suffer from local recurrence
or/and distant metastasis within 2 years. Brain metastases* Correspondence: kongli7@sina.com; sdyujinming@163.com
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unless otherwise stated.(BM) are the most common site of distant failure in
patients with SCLC, regardless of disease stage at presen-
tation. The prevalence of BM detected at the time of
diagnosis ranges from 10% to 24% and the probability of
developing BM during the course of disease increases to
50% by 2 years after diagnosis. BM is associated with a
poor prognosis and the median survival after the develop-
ment of BM is only 4–6 months [3-5].
The survival advantage conferred by prophylactic cra-
nial irradiation (PCI) in patients with SCLC has been
established in recent studies. As a result, PCI has become
part of the standard treatment modality for patients with
SCLC who had stable disease or a better response to ChT,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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The positive role of PCI on patients with SCLC was based
on the two-stage system and treatment modalities of non-
surgery. But the incidence of brain metastases in surgically
treated SCLC and the risk factors for developing BM in
this subgroup were rarely evaluated.
We reviewed the patients with completely resected
SCLC and assessed the possible risk factors for develop-
ing BM in this patient population.
Patients and materials
Study population
We retrospectively reviewed the records of patients with
completely resected SCLC and definitive TNM stage on
the basis of histological examination at the Shandong
Cancer Hospital and Institute between January 2003 and
December 2009. All patients underwent a standardized
evaluation, including thoracic and abdominal computed
tomography scanning or abdominal ultrasonography,
brain magnetic resonance imaging, and bone radio-
nuclide imaging before surgery. All patients had negative
brain computed tomography (CT) scan or magnetic res-
onance imaging (MRI) preoperatively and PCI was not
conducted to them postoperatively. During this period,
211 patients with SCLC were operated in our cancer
center, and 18 patients of them who had R1, R2 resec-
tions were excluded in this study in order to avoid bias
of the results, sixty-seven patients were given PCI, so a
total of 126 patients met the criteria. The study was
approved by the institutional review board and ethics
committee at the Shandong Cancer Hospital and Institute.
Treatment
Surgical procedures included lobectomy or pneumonec-
tomy with ipsilateral hilar and mediastinal lymphadenec-
tomy. Patients received either cisplatin and etoposide
(PE: 30 mg/m2 cisplatin on days 1–3 and either 100 mg/m2
etoposide on days 1–5 or 100 mg/m2 etoposide on days
1–3) or carboplatin and etoposide (CE: carboplatin AUC 5
or 300 mg/m2 on day 1 and either 100 mg/m2 etoposide
on days 1–5 or etoposide 100 mg/m2 on days 1–3). In our
center, postoperative radiotherapy (PORT) was usually
conducted to patients with lymph node metastasis. In this
series, 55 patients were given PORT, 49 patients of them
were staged as N2 and the remaining 6 patients were
staged as N1. The reasons of patients with lymph node
metastasis not accept PORT were as follows: patients re-
fusal, poor lung function or low Karnofsky performance
status (KPS) after surgery. Chemotherapy and radiother-
apy after surgery were given sequentially to 43 patients
and concurrently to 12 patients. TRT was administered
by three-dimensional conformal radiotherapy technique.
The clinical target volume (CTV) included the bronchial
stump, ipsilateral hilum, and adjacent mediastinal lymphnodes, and the planning target volume included the CTV
with a 1-cm margin. Radiation was delivered with mega-
voltage linear accelerators. A total dose of 50–60 Gy was
administered with 1.8–2 Gy per fraction for 5 days a
week.
Statistical analysis
Overall survival (OS) was measured from the date of
surgery to the date of death from any cause or the last
known date that the patient was alive. Time to event of
BM was monitored from the date of surgery to the date
of BM or to the date of last follow-up if no BM oc-
curred. The actuarial risk of developing BM and survival
were estimated by the Kaplan–Meier method. The log-
rank test was used to compare the difference between
groups. Multivariate analyses for BM and OS were per-
formed using Cox regression and a backward-forward
stepwise method was selected. Two-sided p values < 0.05
were considered statistically significant.
Results
Patient characteristics
Records of 126 patients were included and analyzed in
this study. Patient characteristics are summarized in
Table 1. The median follow-up period for all patients
was 56.0 months (range, 30.4–96.8 months). The median
age was 55 years (range, 34–74 years).
Factors predictive of the OS
Median survival time for this patient population was
48.0 months. The OS rates at 2 years and 5 years were
63.2% and 47.8%, respectively (Figure 1). The clinical
and pathological factors evaluated to determine their
prognostic value for OS are summarized in Table 2. Uni-
variate analysis revealed that pathologic(p) -stage and
development of BM were significant factors that corre-
lated with survival rate. The 2-year and 5-year survival
rates were 87.1% and 74.4%, respectively, for patients
with p-stage I disease; 78.6% and 61.7%, respectively, for
patients with p-stage II disease; and 42.6% and 26.6%, re-
spectively, for patients with p-stage III disease (p = 0.001;
Figure 2). Additionally, survival was significantly longer
in the patients who did not develop BM than in patients
who developed BM, with a 2-year and 5-year OS of
69.0% and 56.2% versus 42.9% and 15.5%, respectively
(p = 0.001; Figure 3). Multivariate analysis revealed that
age ≥ 65 years (hazard ratio [HR] = 1.798, p = 0.040),
pathologic stage (HR = 2.093, p = 0.001), and developing
BM (HR = 2.092, p = 0.031) were independent prognostic
factors for OS.
Factors predictive of BM
Twenty-eight patients (28/126, 22.2%) developed BM. The
time for development of BM ranged from 1.3 months to


























No. Cycles of ChT
<4 21 16.7
≥4 105 83.3
Abbreviations: SCLC = small cell lung cancer; KPS = Karnofsky performance
status; P-stage = pathologic stage; LVI = lymphovascular invasion; PORT =
postoperative radiotherapy; ChT = chemotherapy.
Figure 1 Overall survival curve for 126 patients with completely
resected small cell lung cancer.
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10.9 months,which was calculated from the time of diag-
nosis. The incidence of BM was 9.4% (3/32) in patients
with p-stage I disease, 18.2% (6/33) in patients with p-
stage II disease, and 31.1% (19/61) in patients with p-stage
III disease.
The actuarial risk of developing BM in all patients at
1 year and 3 years was 13.8% and 23.0%, respectively.
The clinical and pathological factors evaluated to deter-
mine their prognostic value for the actuarial risk of
developing BM are summarized in Table 3. The risk of
developing BM was associated with pathologic stage.
The actuarial risk of developing BM at 1 year and 3 years
was 3.1% and 9.7%, respectively, in patients with p-stage
I disease; 15.4% and 18.5%, respectively, in patients with
p-stage II disease; and 18.8% and 35.4%, respectively, in
patients with p-stage III disease (p = 0.013, Figure 4).
Lymphovascular invasion (LVI) was also associated with
BM. The risk of developing BM at 1 year and 3 years in
patients with LVI were 30.8% and 39.9%, respectively,
which is significantly higher compared with 9.8% and
17.5% respectively in patients without LVI (p = 0.003;
Figure 5).
Multivariate analysis indicated that pathologic stage
(HR = 2.013, p = 0.017) and LVI (HR = 1.924, p = 0.039)
were independent factors associated with increased risk
of developing BM. Based on the results of the multivari-
ate analysis, we analyzed the effect of these two inde-
pendent high-risk factors affecting the incidence of BM.
In patients with p-stage II disease and LVI (n = 11), the
1-year and 3-year actuarial risk of developing BM was
29.3% and 29.3%, respectively. In patients with p-stage II
disease and no LVI (n = 22), the 1-year and 3-year ac-
tuarial risk of developing BM was 9.1% and 13.6%, re-
spectively. In patients with p-stage III disease and LVI
(n = 17), the 1-year and 3-year actuarial risk of developing
BM was 35.3% and 52.1%, respectively. In patients with
p-stage III disease and no LVI (n = 44), the 1-year and
3-year actuarial risk of developing BM was 12.2% and
27.5%, respectively. The differences among the groups
were statistically significant (p = 0.015). We did not analyze
patients with p-stage I disease because only two patients
with p-stage I disease had LVI.
Discussion
Chemotherapy combined with TRT is the standard treat-
ment for the management of limited-stage (LS) SCLC.
Nevertheless, the role of surgery as a part of multimodality
treatment remains controversial. The NCCN guidelines
recommend lobectomy and mediastinal lymph node dis-
section followed by ChT only for patients who are classi-
fied with clinical stage T1-2 N0 disease and who have
negative pathological mediastinal staging after mediasti-
noscopy [10]. However, if the neoplasm was peripherally
Table 2 Univariate and multivariate analysis of the effect of prognostic factors on OS in patients with resectable SCLC
Factors





X2 p HR 95% CI p
Gender
Male 63.0 48.4
Female 64.0 43.6 0.015 0.901
Age, years
<65 64.8 53.3
≥65 58.9 32.2 3.079 0.079 1.798 1.027 ~ 3.148 0.040
KPS score
≥80 71.5 56.9
<80 61.5 42.3 3.487 0.062 1.149 0.631 ~ 2.092 0.649
Smoking status
Yes 62.1 52.0




III 42.6 26.6 28.70 0.001 2.093 1.399 ~ 3.132 0.001
LVI
Yes 48.6 34.1
No 67.6 51.8 3.358 0.067 0.935 0.507 ~ 1.723 0.829
PORT
Yes 64.7 43.6
No 63.0 48.2 0.028 0.866
Cycle of ChT
<4 61.9 57.1
≥4 63.5 46.0 0.221 0.638
Brain metastasis
Yes 42.9 15.5
No 69.0 56.2 14.65 0.001 2.092 1.049 ~ 4.170 0.031
Abbreviations: OS = overall survival; SCLC = small cell lung cancer; 2y-OS = overall survival rate at 2 years; 5y-OS = overall survival rate at 5 years; HR = hazard ratio; CI =
confidence interval KPS = Karnofsky performance status; P-stage = pathologic stage; LVI = lymphovascular invasion; PORT = postoperative radiotherapy; ChT = chemotherapy.
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enced radiologists, and the result of transthoracic needle
biopsy or bronchoscopy-based biopsy was negative, then
surgery was still performed. In addition, surgery occasion-
ally was performed at the discretion of the surgeons and/
or the patients’ preference.
A favorable role for surgery in LS-SCLC treatment
was alluded to in a Medical Research Council study [11].
However, in this clinical trial, only 34 of the 71 patients
(48%) scheduled to undergo surgery actually underwent
surgery. Not surprisingly, surgery was not found to im-
prove OS in this trial. A randomized Lung Cancer Study
Group study reached a similar conclusion [12]. However,
patients with T1N0 disease were excluded from this trial,
and thus possibly explained the low survival of patientswith early stage SCLC. The role of surgery was re-
evaluated after the recent introduction of the TNM staging
system. A matched-pair analysis comparing 67 patients
who underwent surgery followed by adjuvant ChT and 67
patients who received conventional non-surgical manage-
ment revealed a 5-year OS of 27% for the surgical group
and 4% for the matched non-surgical cohort. Subset
analysis confirmed significantly longer survival following
surgery for T1–2 and N0–1 categories [13]. Several trials
have demonstrated that surgery with adjuvant ChT results
in a favorable survival rate for p-stage I-III disease with a
5-year OS of 31%–71% for patients with p-stage I disease
[14-18]. The data from the Surveillance, Epidemiology,
and End Results registry in 2010 was used to analyze
the role of surgery in patients with localized disease
Figure 2 Comparison of overall survival of patients with surgically
resected small cell lung cancer by pathologic stage.
Table 3 Factors associated with actuarial risk of
developing BM for patients with resectable SCLC
Factors
Univariate analysis Multivariate analysis
1y 3y 3y p HR 95% CI p
Gender
Male 14.3 23.0
Female 12.0 23.6 0.04 0.906
Age, years
<65 14.5 22.4
≥65 12.0 26.3 0.063 0.802
KPS score
≥80 10.6 17.3
<80 16.0 31.5 1.207 0.272
Smoking status
Positive 15.9 24.7




III 18.8 35.4 8.621 0.013 2.013 1.135 ~ 3.569 0.017
LVI
Yes 30.8 39.9
No 9.8 17.5 8.943 0.003 1.924 1.002 ~ 3.291 0.039
PORT
Yes 17.6 33.5
No 13.2 21.3 3.351 0.067 0.825 0.329 ~ 2.064 0.680
Cycle of ChT
<4 10.0 17.5
≥4 14.5 24.2 0.240 0.624
Abbreviations: SCLC = small cell lung cancer; 1y = actuarial risk of developing
BM at 1 year; 3y = actuarial risk of developing BM at 3 years; HR = hazard
ratio; CI = confidence interval; KPS = Karnofsky performance status; P-stage =
pathologic stage; LVI = lymphovascular invasion; PORT = postoperative
radiotherapy; ChT = chemotherapy.
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the 14,179 patients identified, 863 underwent surgical
resection. Surgery was associated with improved sur-
vival for both localized disease and regional disease.
The 5-year OS for patients who received surgery for local-
ized disease was 44.8% compared to an OS of just 13.7%
for the non-surgery group (p < 0.001). In addition, the
5-year OS for patients with regional disease was 26.3%
compared to an OS of 9.3% for the non-surgery group
(p < 0.001). Furthermore, the OS for patients with lymph
node involvement was also improved in the surgery
group [19]. Our study demonstrates that the 5-year OS
of patients with completely resected SCLC was 47.8%,
while the 5-year survival rates for p-stage I, p-stage
II, and p-stage III disease were 74.4%, 61.7%, and 26.6%,
respectively, which are similar to the rates reported by
others.
Additionally, in this series, most patients with lymph node
metastasis were conducted with postoperative radiotherapyFigure 3 Comparison of overall survival between patients based
on development of brain metastases.
Figure 4 The actuarial risk of developing brain metastases
in patients with different pathologic stage of completely
resected SCLC.
Figure 5 The actuarial risk of developing brain metastases
based on the presence or absence of lymphovascular invasion.
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survival benefit to the subgroup.
The positive role of PCI in patients with limited SCLC
and extensive SCLC who achieve a complete response
(CR) to ChT was established in 1999 by a meta-analysis
that included data from seven randomized prospective
studies comparing PCI with no PCI after a CR [6]. The
3-year survival rate was 20.7% for patients who received
PCI compared with 15.3% for those who did not receive
PCI (p = 0.01). The disease-free survival of patients who
received PCI was also improved. The role of PCI on
SCLC was established on the basis of the two-stage
system and the treatment modality of ChT and/or TRT.
However, the use of PCI after combined-modality treat-
ment with surgery for resectable LS-SCLC has not been
investigated sufficiently. The analysis of surgical SCLC
could provide evidence regarding the value of PCI since
these specimens permit accurate pathological diagnosis
and TNM staging. As far as we are aware, only four
studies have evaluated the frequency of BM after surgery
for LS-SCLC. In the study conducted by Gong et al.,
the frequency of BM in patients with p-stage I, II,
and III diseases were 6.25% (2/32), 28.2% (11/39), and
29.1% (16/55), respectively [20]. One Japanese multi-
institutional phase II study (JCOG9101) has reported
that the overall incidence of BM was 15% (9/61) in
patients with surgically resected SCLC, but only 11%
(4/35) in patients with p-stage I disease compared to
19.2% in patients with p-stage II or stage III disease
[15]. Nakamura et al. analyzed the frequency of BM
as a first relapse site and found a 7% (2/30) BM rate
for patients with p-stage I disease, 25% (3/12) for pa-
tients with p-stage II SCLC, and 27% (7/26) for pa-
tients with p-stage III [21]. Ogawa et al. also reported
the frequency of BM, but only 28 patients were in-
cluded in the study [22]. The combined results from these
four studies revealed that BM as the first complicationdeveloped in only 7.2% (8/111) of patients with p-stage I
SCLC, while BM developed in 30.3% (20/66) of pa-
tients with p-stage II and 24.5% (26/106) of patients with
p-stage III.
In our study, we found that the incidence of BM was
only 9.4% (3/32) in patients with p-stage I disease. Simi-
larly, the results of the four studies discussed above also
suggest that PCI maybe not necessary for patients with
p-stage I SCLC. Only one retrospective study has sug-
gested a survival benefit is conferred by the use of PCI
in surgically managed patients with p-stage I and II disease.
In this study, only 39 cases with resected pT1–2 N0–1 M0
LS-SCLC were included, BM-free survival (p = 0.01) and
OS (p = 0.01) were improved in patients who received PCI
[23]. To summarize, the incidence of BM in patients with
p-stage I SCLC was less than 10% and the evidence of
survival benefit of PCI for this subgroup patients was in
shortage, so PCI should be considered cautiously for sur-
gically managed patients with p-stage I SCLC and deserve
further study.
Conclusion
Patients with completely resected p-stage II/III SCLC
and LVI are at the highest risk for BM.
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